Literature DB >> 8258677

Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients.

M Bursztyn1, D Ben-Ishay, M Shochina, J Mekler, I Raz.   

Abstract

OBJECTIVE: To assess the relationship of insulin levels and glucose tolerance to blood pressure in hypertension.
DESIGN: An open, prospective trial of exercise training with ambulatory blood pressure monitoring and intravenous glucose tolerance testing before and after a 14-week training programme. PATIENTS: Twenty sedentary, untreated, non-obese, normoglycaemic individuals of both sexes with uncomplicated essential hypertension, of whom 16 completed the study. INTERVENTION: Fourteen weeks of supervised, low-intensity, group exercise of three 1-h sessions per week. MAIN OUTCOME MEASURES: Ambulatory and clinic blood pressure, and glucose and insulin responses to an intravenous glucose tolerance test.
RESULTS: Maximal work capacity on a bicycle ergometer increased by 20% (P < 0.001); 24-h ambulatory blood pressure was 143 +/- 12/87 +/- 5 mmHg before and 142 +/- 13/87 +/- 7 mmHg after training. Clinic blood pressure decreased from 166 +/- 14/103 +/- 5 mmHg to 157 +/- 12/99 +/- 6 mmHg (P < 0.03). Two-way analysis of variance indicated significant decreases in both glucose (P < 0.04) and insulin (P < 0.03), fasting and throughout the intravenous glucose tolerance test.
CONCLUSIONS: Although mild exercise reduced clinic blood pressure significantly, it did not affect ambulatory blood pressure despite a marked reduction in glucose and insulin levels. This finding argues against a determinant role of insulin in the 24-h maintenance of blood pressure in hypertensive patients under the conditions of the study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258677     DOI: 10.1097/00004872-199310000-00017

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

Review 1.  The role of exercise training in the treatment of hypertension: an update.

Authors:  J M Hagberg; J J Park; M D Brown
Journal:  Sports Med       Date:  2000-09       Impact factor: 11.136

Review 2.  Effects of exercise training on abdominal obesity and related metabolic complications.

Authors:  B Buemann; A Tremblay
Journal:  Sports Med       Date:  1996-03       Impact factor: 11.136

3.  Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.

Authors:  J Cléroux; R D Feldman; R J Petrella
Journal:  CMAJ       Date:  1999-05-04       Impact factor: 8.262

4.  Exercise training enhanced the expression of myocardial proteins related to cell protection in spontaneously hypertensive rats.

Authors:  Claude Lajoie; Angelino Calderone; Louise Béliveau
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

Review 5.  Acute and chronic effects of aerobic and resistance exercise on ambulatory blood pressure.

Authors:  Crivaldo Gomes Cardoso; Ricardo Saraceni Gomides; Andréia Cristiane Carrenho Queiroz; Luiz Gustavo Pinto; Fernando da Silveira Lobo; Tais Tinucci; Décio Mion; Claudia Lucia de Moraes Forjaz
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

6.  Improvements in insulin sensitivity and muscle blood flow in aerobic-trained overweight-obese hypertensive patients are not associated with ambulatory blood pressure.

Authors:  Paulo H Waib; Maria I Gonçalves; Silvia R Barrile
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-12-10       Impact factor: 3.738

7.  The metabolic syndrome and the immediate antihypertensive effects of aerobic exercise: a randomized control design.

Authors:  Linda S Pescatello; Bruce E Blanchard; Jaci L Van Heest; Carl M Maresh; Heather Gordish-Dressman; Paul D Thompson
Journal:  BMC Cardiovasc Disord       Date:  2008-06-10       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.